OncoZenge Feed

	Est. tid*
2026-11-11	08:00	Kvartalsrapport 2026-Q3
2026-09-03	08:00	Kvartalsrapport 2026-Q2
2026-05-28	-	X-dag ordinarie utdelning ONCOZ 0.00 SEK
2026-05-27	-	Årsstämma
2026-05-26	-	Kvartalsrapport 2026-Q1
2026-02-26	-	Bokslutskommuniké 2025
2025-10-30	-	Kvartalsrapport 2025-Q3
2025-08-21	-	Kvartalsrapport 2025-Q2
2025-05-30	-	X-dag ordinarie utdelning ONCOZ 0.00 SEK
2025-05-28	-	Årsstämma
2025-05-15	-	Kvartalsrapport 2025-Q1
2025-03-03	-	Extra Bolagsstämma 2025
2025-02-20	-	Bokslutskommuniké 2024
2024-11-18	-	Kvartalsrapport 2024-Q3
2024-08-09	-	Kvartalsrapport 2024-Q2
2024-06-03	-	X-dag ordinarie utdelning ONCOZ 0.00 SEK
2024-05-31	-	Årsstämma
2024-05-21	-	Kvartalsrapport 2024-Q1
2024-02-15	-	Bokslutskommuniké 2023
2023-11-01	-	Extra Bolagsstämma 2023
2023-10-31	-	Kvartalsrapport 2023-Q3
2023-08-31	-	Kvartalsrapport 2023-Q2
2023-06-01	-	X-dag ordinarie utdelning ONCOZ 0.00 SEK
2023-05-31	-	Årsstämma
2023-05-16	-	Kvartalsrapport 2023-Q1
2023-02-14	-	Bokslutskommuniké 2022
2022-11-15	-	Kvartalsrapport 2022-Q3
2022-08-16	-	Kvartalsrapport 2022-Q2
2022-05-24	-	X-dag ordinarie utdelning ONCOZ 0.00 SEK
2022-05-23	-	Årsstämma
2022-05-17	-	Kvartalsrapport 2022-Q1
2022-02-15	-	Bokslutskommuniké 2021
2021-12-07	-	Extra Bolagsstämma 2021
2021-11-16	-	Kvartalsrapport 2021-Q3
2021-08-17	-	Kvartalsrapport 2021-Q2
2021-05-18	-	Kvartalsrapport 2021-Q1

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2026-06-05 15:10:00 OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement 6,32 SEK | -0,32% | 0,28 MSEK

2026-06-03 09:30:00 OncoZenge AB Appoints Linda Nord as Head of Regulatory Affairs 6,49 SEK | -3,42% | 0,21 MSEK

2026-06-02 09:50:00 OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici 6,72 SEK | +6,67% | 0,59 MSEK

2026-05-27 15:15:00 KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOZENGE 6,73 SEK | -10,27% | 0,70 MSEK

2026-05-27 15:15:00 BULLETIN FROM THE ANNUAL GENERAL MEETING OF ONCOZENGE 6,73 SEK | -10,27% | 0,70 MSEK

2026-05-26 11:20:00 OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge™ 7,50 SEK | -0,92% | 2,13 MSEK

2026-05-26 08:00:00 OncoZenge AB Interim Report January 1 - March 31, 2026 7,50 SEK | -0,92% | 2,13 MSEK

2026-05-22 07:00:00 OncoZenge enters into a loan agreement of SEK 2 million with Linc AB 7,28 SEK | +2,82% | 0,42 MSEK

2026-05-19 13:40:00 OncoZenge Provides Regulatory Update on BupiZenge™ Phase III Trial 6,80 SEK | +3,03% | 0,39 MSEK

2026-04-30 08:00:00 OncoZenge AB publicerar årsredovisning för 2025 6,00 SEK | -5,96% | 0,09 MSEK

2026-04-30 08:00:00 OncoZenge AB Publishes Annual Report for 2025 6,00 SEK | -5,96% | 0,09 MSEK

2026-04-28 14:50:00 OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial (‘BEAM-Pain’) of BupiZenge™ from European Authorities 6,17 SEK | +3,70% | 0,35 MSEK

2026-04-24 08:00:00 Notice of the Annual General Meeting of OncoZenge AB (publ) 5,81 SEK | +1,75% | 0,20 MSEK

2026-04-24 08:00:00 Kallelse till årsstämma i OncoZenge AB (publ) 5,81 SEK | +1,75% | 0,20 MSEK

2026-04-02 12:55:00 OncoZenge Confirms Submission of Responses to EMA on the BupiZenge™ Phase III Trial (BZ003) 5,70 SEK | -0,35% | 0,02 MSEK

2026-04-01 09:15:00 OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial 5,72 SEK | +3,81% | 0,22 MSEK

2026-02-26 08:00:00 OncoZenge AB Year-end Report January 1 – December 31, 2025 5,99 SEK | +3,81% | 0,07 MSEK

2026-02-12 10:22:00 OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical 5,81 SEK | +2,83% | 0,19 MSEK

2026-02-04 09:40:00 OncoZenge AB Unveils Key Insights from UCLA Patient Engagement Study on Oral Mucositis Pain Management 5,64 SEK | +10,16% | 0,19 MSEK

2026-02-02 09:30:00 OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer 5,16 SEK | -0,58% | 0,07 MSEK

2026-01-30 15:40:00 OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge™ Technology Batch, Advancing Toward Clinical Trials 5,19 SEK | -4,07% | 0,23 MSEK

2026-01-22 19:19:00 OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds 5,64 SEK | +8,67% | 0,22 MSEK

2026-01-21 17:32:00 OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact 5,19 SEK | -11,13% | 0,76 MSEK

2025-12-19 08:50:00 OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement 6,17 SEK | +0,98% | 0,10 MSEK

2025-12-18 17:23:00 OncoZenge Submits Clinical Trial Application for Pivotal Phase III Trial (BZ003) of BupiZenge™ 6,11 SEK | -4,08% | 0,15 MSEK

2025-12-03 08:45:00 OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge™ for Europe 6,71 SEK | +10,18% | 0,67 MSEK

2025-11-17 10:00:00 OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge™ 5,90 SEK | -7,38% | 0,04 MSEK

2025-10-30 08:00:00 OncoZenge AB Interim Report January 1 – September 30, 2025 5,59 SEK | +0,54% | 0,12 MSEK

2025-10-09 08:45:00 OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study 5,99 SEK | +6,77% | 0,51 MSEK

2025-10-08 19:50:00 OncoZenge AB Nomination Committee Appointed 5,99 SEK | +6,77% | 0,51 MSEK

2025-09-22 15:20:00 OncoZenge AB - Capital Markets Day 2025 On-Demand Video Now Available 6,11 SEK | -3,02% | 0,39 MSEK

2025-09-17 08:50:00 OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™ 6,30 SEK | +1,78% | 0,33 MSEK

2025-09-10 17:10:00 OncoZenge AB appoints LINK Medical as CRO for BupiZenge™ Phase III execution 6,85 SEK | +5,71% | 1,38 MSEK

2025-08-27 16:00:00 Invitation to OncoZenge's Capital Markets Day on 18 September 2025 6,59 SEK | +1,07% | 0,60 MSEK

2025-08-21 08:00:00 OncoZenge AB Interim Report January 1 – June 30, 2025 7,62 SEK | +3,11% | 0,55 MSEK

2025-08-13 11:35:00 OncoZenge Event Calendar September – December 2025 6,20 SEK | -3,58% | 0,24 MSEK

2025-08-13 10:55:52 OncoZenge ändrar bolagets rapportering till engelska 6,20 SEK | -3,58% | 0,24 MSEK

2025-08-13 10:55:52 OncoZenge Changes Reporting Language to English 6,20 SEK | -3,58% | 0,24 MSEK

2025-07-30 08:50:00 OncoZenge Provides Market and Strategy Update 6,68 SEK | +1,37% | 0,34 MSEK

2025-07-21 09:50:00 OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 Project 6,95 SEK | +2,06% | 0,23 MSEK

2025-07-21 09:50:00 OncoZenge utser Meribel Pharma som CDMO för BupiZenge™ Fas 3-projektet 6,95 SEK | +2,06% | 0,23 MSEK

2025-07-17 08:45:00 OncoZenge och Molteni Farmaceutici undertecknar tilläggsavtal för att fokusera BupiZenge™ fas 3-projekt i Europa 6,52 SEK | -3,26% | 0,59 MSEK

2025-07-17 08:45:00 OncoZenge and Molteni Farmaceutici Sign Amendment to Focus BupiZenge™ Phase 3 Project in Europe 6,52 SEK | -3,26% | 0,59 MSEK

2025-07-11 11:15:00 OncoZenge erhåller investeringslikvid från Yangtian Bio-Pharmaceutical 7,58 SEK | +18,81% | 1,36 MSEK

2025-07-11 11:15:00 OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical 7,58 SEK | +18,81% | 1,36 MSEK

2025-07-09 08:50:00 OncoZenge AB ingår avtal om konvertibellån med Linc AB 6,27 SEK | +2,62% | 0,37 MSEK

2025-07-09 08:50:00 OncoZenge AB Enters into Convertible Loan Agreement with Linc AB 6,27 SEK | +2,62% | 0,37 MSEK

2025-07-08 10:00:00 OncoZenge Appoints Tuulikki Lindmark as Head of CMC in Phase 3 Sponsor Team 6,11 SEK | -4,23% | 0,40 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

OncoZenge

Prenumeration

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

OncoZenge

Prenumeration

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden